Overcoming Drug Resistance by Regulating Nuclear Receptors

Overview

Journal Adv Drug Deliv Rev

Specialty Pharmacology

Date 2010 Aug 10

PMID 20691230

Citations 36

Authors

Taosheng Chen

Affiliations

Soon will be listed here.

Abstract

Drug resistance involves multiple mechanisms. Multidrug resistance (MDR) is the leading cause of treatment failure in cancer therapy. Elevated levels of MDR proteins [members of the ATP-binding cassette (ABC) transporter family] increase cellular efflux and decrease the effectiveness of chemotherapeutic agents. As a salvage approach to overcome drug resistance, inhibitors of MDR proteins have been developed, but have had limited success mainly due to undesired toxicities. Nuclear receptors (NRs), including pregnane X receptor (PXR), regulate the expression of proteins (including MDR proteins) involved in drug metabolism and drug clearance, suggesting that it is possible to overcome drug resistance by regulating NR. This review discusses the progress in the development of MDR inhibitors, with a focus on MDR1 inhibitors. Recent development of PXR antagonists to pharmacologically modulate PXR is also reviewed. The review proposes that selectively preventing the elevation of MDR levels by regulating NRs rather than non-selectively inhibiting the MDR activity by using MDR inhibitors can be a less toxic approach to overcome drug resistance during cancer therapy.

Citing Articles

Silencing of Epidermal Growth Factor-like Domain 8 Promotes Proliferation and Cancer Aggressiveness in Human Ovarian Cancer Cells by Activating ERK/MAPK Signaling Cascades.

Song Y, Kim J, Rajbongshi L, Lim Y, Ok Y, Hwang S Int J Mol Sci. 2025; 26(1.

PMID: 39796130 PMC: 11720593. DOI: 10.3390/ijms26010274.

Chemical manipulation of an activation/inhibition switch in the nuclear receptor PXR.

Garcia-Maldonado E, Huber A, Chai S, Nithianantham S, Li Y, Wu J Nat Commun. 2024; 15(1):4054.

PMID: 38744881 PMC: 11094003. DOI: 10.1038/s41467-024-48472-1.

Natural compounds targeting nuclear receptors for effective cancer therapy.

Hegde M, Girisa S, Naliyadhara N, Kumar A, AlQahtani M, Abbas M Cancer Metastasis Rev. 2022; 42(3):765-822.

PMID: 36482154 DOI: 10.1007/s10555-022-10068-w.

Combination of Paclitaxel and PXR Antagonist SPA70 Reverses Paclitaxel-Resistant Non-Small Cell Lung Cancer.

Niu X, Wu T, Yin Q, Gu X, Li G, Zhou C Cells. 2022; 11(19).

PMID: 36231056 PMC: 9563422. DOI: 10.3390/cells11193094.

Nuclear Receptor PXR Confers Irradiation Resistance by Promoting DNA Damage Response Through Stabilization of ATF3.

Niu X, Cui H, Gu X, Wu T, Sun M, Zhou C Front Oncol. 2022; 12:837980.

PMID: 35372071 PMC: 8965888. DOI: 10.3389/fonc.2022.837980.

References

Dubrac S, Elentner A, Ebner S, Horejs-Hoeck J, Schmuth M . Modulation of T lymphocyte function by the pregnane X receptor. J Immunol. 2010; 184(6):2949-57. DOI: 10.4049/jimmunol.0902151. View

Masuyama H, Hiramatsu Y, Mizutani Y, Inoshita H, Kudo T . The expression of pregnane X receptor and its target gene, cytochrome P450 3A1, in perinatal mouse. Mol Cell Endocrinol. 2001; 172(1-2):47-56. DOI: 10.1016/s0303-7207(00)00395-6. View

Raynal C, Pascussi J, Leguelinel G, Breuker C, Kantar J, Lallemant B . Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol Cancer. 2010; 9:46. PMC: 2838814. DOI: 10.1186/1476-4598-9-46. View

Pondugula S, Brimer-Cline C, Wu J, Schuetz E, Tyagi R, Chen T . A phosphomimetic mutation at threonine-57 abolishes transactivation activity and alters nuclear localization pattern of human pregnane x receptor. Drug Metab Dispos. 2009; 37(4):719-30. PMC: 2680541. DOI: 10.1124/dmd.108.024695. View

Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Backman M . Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A. 1998; 95(21):12208-13. PMC: 22810. DOI: 10.1073/pnas.95.21.12208. View

Cordon-Cardo C, OBrien J, CASALS D, Biedler J, Melamed M, Bertino J . Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A. 1989; 86(2):695-8. PMC: 286540. DOI: 10.1073/pnas.86.2.695. View

Cordon-Cardo C, OBrien J, Boccia J, CASALS D, Bertino J, Melamed M . Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 1990; 38(9):1277-87. DOI: 10.1177/38.9.1974900. View

Burk O, Arnold K, Geick A, Tegude H, Eichelbaum M . A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression. Biol Chem. 2005; 386(6):503-13. DOI: 10.1515/BC.2005.060. View

Bauer B, Hartz A, Fricker G, Miller D . Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol. 2004; 66(3):413-9. DOI: 10.1124/mol.66.3.. View

10.

Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y . Down-regulation of pregnane X receptor contributes to cell growth inhibition and apoptosis by anticancer agents in endometrial cancer cells. Mol Pharmacol. 2007; 72(4):1045-53. DOI: 10.1124/mol.107.037937. View

11.

Harasym T, Liboiron B, Mayer L . Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention. Methods Mol Biol. 2009; 596:291-323. DOI: 10.1007/978-1-60761-416-6_13. View

12.

Zhang Y, Benet L . The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet. 2001; 40(3):159-68. DOI: 10.2165/00003088-200140030-00002. View

13.

Baer M, George S, Dodge R, OLoughlin K, Minderman H, Caligiuri M . Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 2002; 100(4):1224-32. View

14.

Goodwin B, Hodgson E, Liddle C . The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol. 1999; 56(6):1329-39. DOI: 10.1124/mol.56.6.1329. View

15.

Synold T, Dussault I, Forman B . The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med. 2001; 7(5):584-90. DOI: 10.1038/87912. View

16.

Cole S, Bhardwaj G, Gerlach J, MACKIE J, Grant C, Almquist K . Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992; 258(5088):1650-4. DOI: 10.1126/science.1360704. View

17.

Greiner B, Eichelbaum M, Fritz P, Kreichgauer H, von Richter O, Zundler J . The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 1999; 104(2):147-53. PMC: 408477. DOI: 10.1172/JCI6663. View

18.

Schinkel A, Smit J, van Tellingen O, Beijnen J, Wagenaar E, van Deemter L . Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994; 77(4):491-502. DOI: 10.1016/0092-8674(94)90212-7. View

19.

Geick A, Eichelbaum M, Burk O . Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001; 276(18):14581-7. DOI: 10.1074/jbc.M010173200. View

20.

Szakacs G, Paterson J, Ludwig J, Booth-Genthe C, Gottesman M . Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3):219-34. DOI: 10.1038/nrd1984. View